Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma

ALK-positive Anaplastic Large Cell Lymphoma (ALCL) represents a subset of Non-Hodgkin Lymphoma whose treatment benefited from crizotinib development, a dual ALK/MET inhibitor. Crizotinib blocks ALK-triggered pathways such as PI3K/AKT/mTOR, indispensable for survival of ALK-driven tumors. Despite the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Redaelli, Sara, Ceccon, Monica, Antolini, Laura, Rigolio, Roberta, Pirola, Alessandra, Peronaci, Marco, Gambacorti-Passerini, Carlo, Mologni, Luca
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341951/
https://ncbi.nlm.nih.gov/pubmed/27662658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12128
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars